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Abstract
Inheritance of germline BRCA1 mutations is associated with a high risk of breast and ovarian
cancers. A multitude of cellular functions has been ascribed to BRCA1, including trans-
cription activation and various aspects of DNA repair. So far, indirect evidence has indicated
a role for BRCA1 in the repair of double-strand breaks. Recently, an elegant gene targeting
design was used to provide definitive evidence that BRCA1 promotes homologous
recombination and limits nonhomologous mutagenic repair processes. This reaffirms the role
of BRCA1 as caretaker in preserving genomic integrity.
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Introduction
Ever since the cloning of the two breast cancer suscepti-
bility genes BRCA1 and BRCA2, intense scientific effort
has been invested into elucidating their biologic functions.
Both genes encode large proteins (1863 and 3418 amino
acids, respectively) that are coordinately expressed during
cellular proliferation and differentiation [1]. The BRCA1
and BRCA2 proteins are expressed in most tissues and
most abundantly during the S phase of the cell cycle. A
plethora of functions have been ascribed to BRCA1 and
BRCA2, including transcription activation [2–4], chro-
matin remodelling [5,6], centrosome duplication [7,8],
apoptosis [9], and transcription-coupled [10] and homol-
ogy directed [11–13] DNA repair.
Murine models for BRCA1 and BRCA2 mutations estab-
lish that both genes are essential for development
[14–17], because early embryonic lethality is a common
phenotype. This early lethal phenotype can be partly
rescued by introducing a null mutation in the damage
checkpoint gene p53 or p21 [18]. This suggests that loss
of BRCA1 or BRCA2 may trigger the activation of a cell-
cycle checkpoint through the accumulation of DNA
damage. In agreement with this, both Brca1–/– and
Brca2–/– homozygous cells have been found to be hyper-
sensitive to g-irradiation [17,18] and spontaneously exhibit
chromosomal abnormalities [11,13].
The first indication that BRCA1 and BRCA2 function in
homologous recombination came from coimmunoprecipi-
tation and yeast two-hybrid studies [17,19,20], which
demonstrated that both BRCA1 and BRCA2 interacted
with Rad51, a mammalian homologue of the Escherichia
coli RecA protein that is involved in DNA damage repair.
(The association of BRCA1 with Rad51, however, is likely
to be indirect and possibly mediated by BRCA2 [21]).http://breast-cancer-research.com/content/2/2/082
Immunostaining further suggests that BRCA1, BRCA2
and Rad51 work together in a protein complex as they
coalesce to form discrete nuclear dots during S phase
and after DNA damage [21,22]. Moreover, in meiotic cells
extensive colocalization of BRCA1, BRCA2 and Rad51
have been demonstrated on synaptonemal complexes [21].
As already mentioned, Rad51 is part of homologous
recombination. In E coli, and the budding yeast Saccha-
romyces cerevisiae, homologous recombination is a major
pathway for repairing double-strand breaks (although no
homologues of BRCA1 or BRCA2 have yet been identi-
fied in these organisms). In mammalian cells, it has been
estimated that around 30–50% of DNA breaks are
repaired by homologous recombination [23], the remain-
der being dealt with mainly by a process known as nonho-
mologous end-joining (NHEJ). Unlike homologous
recombination, which repairs through genetic exchange
with a homologous chromosome, NHEJ simply involves
direct joining of the broken ends. This frequently results in
small deletions or insertions at the site of breakage.
Whereas NHEJ is a relatively well-understood pathway in
mammalian cells [24], little is known about the mecha-
nisms involved in mammalian homologous recombination.
Despite all speculations that BRCA1 and BRCA2 partici-
pate in Rad51-mediated homologous recombination,
direct evidence is lacking. Furthermore, to delineate the
players involved in homologous recombination in mam-
malian cells, it is necessary to have a robust reporter
assay system. It is to this challenge that Jasin [25] pro-
vided a valuable tool.
BRCA1 controls homologous recombination
A Brca1-deficient murine embryonic stem cell line devel-
oped by Gowen et al [14] was employed. The mutant
Brca1 gene here was created by replacing the terminal
portion of intron 10 and the beginning of exon 11 with a
selectable marker gene, resulting in the loss of the full-
length Brca1 transcript. Exon 11 is the largest coding
exon of Brca1 and encodes approximately 60% of the
protein, including the putative Rad51-interacting domain
[20]. Murine embryos that harbour the Brca1 mutation
described by Gowen et al [14] typically survive to embry-
onic day 9 or 10.
Moynahan  et al [12] devised two assays to test the
integrity of homologous recombination in the Brca1–/–
embryonic stem cells. First, the rate of targeted integration
of transfected DNA was evaluated (Fig. 1). Moynahan et al
found that gene-targeting efficiency was 23-fold lower in
Brca1–/– cells when the promotorless pim1-Q targeting
vector was transfected. This was not due to the lack of a
promotor, because when an Rb-O targeting vector that
contained a pgk promoter was used, Brca1–/– cells had a
13-fold decrease in gene targeting and a fourfold increase
in random integration compared with Brca1+/– control cells.
Next, Moynahan and colleagues tested the ability of
Brca1-deficient cells to repair chromosomal double-strand
breaks. They made use of a rare-cutting endonuclease,
I-SceI, which has a unique 18-base-pair nonpalindromic
recognition sequence that is not found in the mammalian
genome [26]. A direct repeat recombination substrate
containing this sequence was integrated at the pim1 and
Rb loci. Introduction of the enzyme I-SceI would, therefore,
create a double-strand break (DSB) in the direct repeat
that consisted of two differentially mutated neomycin
phosphotransferase (neo) genes separated by a thymidine
kinase (tk) gene (Fig. 2). It has already been demonstrated
that the presence of a single DSB was a potent stimulus
for homologous recombination [25]. By selecting for the
loss of the tk gene, it would be possible to estimate the
frequency of deletional homologous recombination (Fig.
2). In agreement with the previous assay, the Brca1–/– cell
line exhibited a fivefold lower frequency of spontaneous
and DSB-induced deletion compared with the heterozy-
gous control. This was further supported by detailed
examination of the substrates by polymerase chain reac-
tion and Southern blotting.
Using primers flanking the DSB site and the NcoI site in
the substrate (Fig. 2), Moynahan et al [12] were able to
distinguish end-products from both homologous recombi-
nation and NHEJ. They concluded that Brca1–/– cells had
a consistently fivefold to sixfold lower level of homologous
recombination by both noncrossover gene conversion and
deletion. On the contrary, NHEJ was intact and its fre-
quency was even increased by 1.5-fold to 1.6-fold in
Brca1–/– cells.
Conclusion
The work of Moynahan et al [12] is significant, because it
is the first direct demonstration of the role of Brca1 in con-
trolling homologous recombination. Cells deficient in
Figure 1
Schematic representations of the (A) pim1-Q and (B) Rb-O targeting
vectors. (A) Gene targeting strategy at the pim1 locus. Expression of
the promotorless hygromycin resistance relies on the endogenous
pim1 promotor once it is integrated by homologous recombination.
Transfected cells are selected in hygromycin. (B) Gene targeting
strategy at the Rb locus. The Rb-O contains a hygromycin gene
expressed from a pgk promotor. Therefore, hygromycin resistance is
exhibited regardless of the site of integration
Hyg Sneo Pneo tk
Rb-O
Pim1-Q
Hyg Sneo Pneo tk A
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Brca1 were found to have decreased gene targeting as
well as impaired homologous recombination of an experi-
mentally introduced DSB. Interestingly, the rate of homolo-
gous recombination in Brca1–/– embryonic stem cells was
reduced by around fivefold, but was not absent. The
authors proposed that this was due to the particular
Brca1–/– cell line chosen. The mutation in the Brca1 gene
apparently does not produce a complete null allele,
because an in-frame fusion product is formed from expres-
sion of an exon 10 12 splice variant [12]. In this Brca1–/–
cell line, Rad51 focus formation following DNA damage is
partly, but not totally defective. This may explain the rela-
tive, but not complete loss of homologous recombination
in these cells. Alternatively, the partial Brca1 product
expressed might not have any role in homologous recom-
bination, but other as yet unidentified Brca1-independent
pathways that govern homologous recombination could
be responsible for the residual recombination observed.
This work also raises other interesting questions. For
example, an increase in random integration of transfected
DNA was observed. As Moynahan et al [12] suggested,
this could be a direct result of increased NHEJ, or simply
due to the elevated level of spontaneous DSBs in the
genome into which transfected DNA could insert. Alterna-
tively, other undefined mutagenic mechanisms may be at
work, because evidence is now gathering that multiple
DNA repair pathways can potentially compete for the
same repair substrate, in this case the DSB [27,28].
It has been suggested that Brca1 plays a crucial role in
maintaining genetic stability. Like Brca2-deficient cells
[13], Brca1-deficient murine [11] and human [29] cells
have been reported to exhibit spontaneous chromosomal
aberrations. This is akin to the gross chromosomal aberra-
tions that are typical of chromosome instability disorders
such as Bloom syndrome, Werner syndrome, Nijmegen
breakage syndrome and ataxia–telangiectasia [30]. The
mechanism for the maintenance of genetic stability is not
known, but it has been suggested that genes that are
mutated in the chromosome instability syndromes function
as ‘caretakers’ [31] to prevent the occurrence of gross
chromosomal rearrangements. Most of these genes partic-
ipate in some aspect of DNA damage recognition and/or
repair, and Brca1 has been shown to interact with at least
two of them. For example, Brca1 associates with the
hRad50-hMre11-p95/nibrin complex (nibrin is the gene
mutated in Nigmegen breakage syndrome) in response to
irradiation [32]. These nuclear foci are distinct from the
Rad51 foci described earlier, suggesting Brca1 may par-
ticipate in more than one damage response pathway.
Recently, Cortez et al [33] provided evidence that the
DNA damage sensor ATM (the gene mutated in
ataxia–telengiectasia) was required for the phosphoryla-
tion of Brca1 in response to DSBs. A model is now
emerging in which phosphorylation of Brca1 by ATM
recruits or regulates multiple repair pathways that may
involve the hRad50-hMre11-p95/nibrin complex, transcrip-
tion coupled repair, or Rad51-mediated homologous
recombination [34].
Homologous recombination may be an important mecha-
nism for maintaining genetic stability. Evidence already
exists that cells that harbour mutations in other genes in
the Rad51-family, XRCC2 and XRCC3, are defective in
homologous recombination [35,36] and exhibit sponta-
neous chromosome instability [37,38]. It is not yet known
what pathways are responsible for generating the abnor-
mal chromosomes in the absence of normal homologous
recombination. Cells that are defective in NHEJ per se do
not exhibit abnormal chromosomes [39]. In Brca1-defi-
cient cells, Moynahan et al [12] believe that nonhomolo-
gous processes may promote aberrant types of repair.
Interestingly, Brca2-deficient cells that exhibit gross chro-
mosomal aberrations also have intact NHEJ [13]. Although
this idea is very plausible, further studies are required to
clarify this issue.
Finally, the correlation between chromosomal instability
and cancer has long been known, but we are just begin-
ning to unravel the mechanisms responsible for maintain-
ing genetic stability. As the number of potential candidates
for homologous recombination increases, the strategy
devised by Moynahan et al [12] remains a useful screen-
ing tool. Although our understanding of homologous
recombination in mammalian cells is still in its infancy, the
enormous research interest in the field means that our
understanding will move at a considerable speed. At this
juncture, one can only say ‘watch this space’ – knowledge
of the caretakers of the genome may one day change the
manner in which we manage cancers.
Figure 2
Outcomes of the repair of a double-strand break (DSB) introduced by
I-SceI. (A) The integrated pim1-Q vector. Open arrows indicate the
positions of PCR primers that are used to distinguish between the
various repair products. (B) Possible repair products. NHEJ,
nonhomologous end-joining.
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